Indication
Transplant Glomerulopathy
2 clinical trials
1 product
Clinical trial
A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) to Eliminate Donor Specific HLA Antibodies (DSAs) and Improve Transplant Rates in Highly-HLA Sensitized Patients Awaiting Renal TransplantStatus: Active (not recruiting), Estimated PCD: 2025-07-30
Product
ClazakizumabClinical trial
A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) As an Agent to Eliminate Donor Specific HLA Antibodies and Improve Outcomes of Patients With Chronic & Active Antibody-Mediated Rejection Post-Kidney TransplantationStatus: Completed, Estimated PCD: 2024-04-16